ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Alentis Therapeutics has raised $181.4M in total funding. The most recent round was Series D. The last funding was announced in November 2024.
Alentis Therapeutics's investors include RA Capital Management, Bpifrance, HTGF (High-Tech Gruenderfonds), Schroders Capital, Catalio Capital Management.
Alentis Therapeutics is headquartered in Allschwil, Switzerland.
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Alentis Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alentis Therapeutics — Funding & Investors." VCBacked, November 12, 2024, https://www.vcbacked.co/company/alentis-therapeutics. Accessed August 1, 2026.
VCBacked. (2024). Alentis Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/alentis-therapeutics
{{cite web |title=Alentis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alentis-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated